Faeth Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-21.1M | $-30.2M | $-34.1M | $-48.6M | $-36.8M | $-20.1M |
| Depreciation & Amortization | $122.0K | $551.0K | $571.0K | $614.0K | $685.0K | $209.0K |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $1.3M | $3.1M | $4.5M | $5.8M | $5.7M | $1.5M |
| Net Cash from Operating Activities | $-20.5M | $-24.7M | $-32.0M | $-39.0M | $-30.3M | $-17.7M |
| Investing Activities | ||||||
| Capital Expenditures | $16.0K | $146.0K | $180.0K | $321.0K | $2.0M | $1.2M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $19.8M | $22.4M | $38.4M | $49.9M | $-143.1M | $-1.4M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | $10.4M | — | — | — |
| Net Cash from Financing Activities | $-645.0K | $-787.0K | $-11.2M | $-287.0K | $163.9M | $35.5M |
| Net Change in Cash | $-1.3M | $-3.0M | $-4.8M | $10.6M | $-9.4M | $16.3M |
| Free Cash Flow | $-20.5M | $-24.8M | $-32.2M | $-39.3M | $-32.3M | $-18.9M |